The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Renaissance of the Blocking Antibody Concept in Type I Allergy
Abstract
Formation of IgE antibodies against per se harmless antigens (i.e. allergens) is the hallmark and key pathomechanism of type I allergy, a hypersensitivity disease affecting more than 25% of the population. Classical experiments performed more than 65 years ago demonstrated that allergen-specific IgG antibodies, termed blocking antibodies, can antagonize the cascade of allergic inflammation resulting from allergen recognition by IgE antibodies. However, controversial results have questioned the protective role of IgG antibodies in allergic diseases. Here, we review recent data demonstrating that blocking antibodies inhibit allergen-induced release of inflammatory mediators from basophils and mast cells as well as IgE-facilitated allergen presentation to T cells, thus leading to suppression of T cell activation. Furthermore, it has been reported that the development of blocking antibodies is associated with reduced boosts of allergen-specific IgE production in patients receiving allergen-specific immunotherapy. These findings suggest that blocking antibodies have protective activity by inhibiting immediate as well as late inflammatory responses and long-term ameliorating activity on the allergic immune response by antagonizing the underlying IgE production. Induction of blocking antibodies is thus an important mechanism underlying allergen-specific immunotherapy. In addition, passive administration of blocking antibodies may be considered as a potential therapeutic strategy for allergic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kay, A. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440106 · Cited by 1,368
DIAGNOSIS OF ALLERGY BY AN IN-VITRO TEST FOR ALLERGEN ANTIBODIES
Wide, L., Bennich, H., & Johansson, S. G. O. (1967) · The Lancet · doi:10.1016/s0140-6736(67)90615-0 · Cited by 1,253
THE HIGH-AFFINITY I g E RECEPTOR (FcεRI): From Physiology to Pathology
Kinet, J.-P. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.931 · Cited by 968
Signal Transduction by the High-Affinity Immunoglobulin E Receptor FcεRI: Coupling Form to Function
Nadler, M. J. S., Matthews, S. A., Turner, H., & Kinet, J.-P. (2001) · Advances in Immunology · doi:10.1016/s0065-2776(01)76022-1 · Cited by 203
Cited by
Akdis, M., & Akdis, C. A. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.12.1088 · Cited by 565
Burks, A. W., Calderon, M. A., Casale, T., Cox, L., Demoly, P., Jutel, M., Nelson, H., & Akdis, C. A. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.01.049 · Cited by 438
The Role of Protein Glycosylation in Allergy
Altmann, F. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000096114 · Cited by 393
Shamji, M. H., Ljørring, C., Francis, J. N., A Calderon, M., Larché, M., Kimber, I., Frew, A. J., Ipsen, H., Lund, K., Würtzen, P. A., et al. (2012) · Allergy · doi:10.1111/j.1398-9995.2011.02745.x · Cited by 297
Immune mechanisms of allergen‐specific sublingual immunotherapy
Moingeon, P., Batard, T., Fadel, R., Frati, F., Sieber, J., & Van Overtvelt, L. (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01002.x · Cited by 290
Metadata
- Authors
- Flicker, S., & Valenta, R.
- Venue
- International Archives of Allergy and Immunology
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 132
- Issue
- 1
- Pages
- 13-24
- ISSN
- 1018-2438 (ISSN-L)
- 1423-0097
- OpenAlex
- W1974829009
- Cited by
- 163
- References
- 4
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renaissance of the Blocking Antibody Concept in Type I Allergy. https://app.cochat.ai/papers/10.1159/000073260
- The paper
- Flicker, S., & Valenta, R. (2003). Renaissance of the Blocking Antibody Concept in Type I Allergy. International Archives of Allergy and Immunology. https://doi.org/10.1159/000073260
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.